- Home
- LVS vs DXCM Comparison
LVS vs DXCM Comparison
Compare LVS & DXCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LVS | DXCM |
|---|---|---|
| Founded | 1988 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.5B | 31.7B |
| IPO Year | 2004 | 2005 |
Fundamental Metrics
Financial Performance| Metric | LVS | DXCM |
|---|---|---|
| Price | $69.73 | $63.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 21 |
| Target Price | $65.60 | ★ $87.24 |
| AVG Volume (30 Days) | 5.3M | ★ 7.5M |
| Earning Date | 10-22-2025 | 10-30-2025 |
| Dividend Yield | ★ 1.44% | N/A |
| EPS Growth | ★ 9.73 | 7.75 |
| EPS | ★ 2.22 | 1.80 |
| Revenue | ★ $12,264,000,000.00 | $4,515,900,000.00 |
| Revenue This Year | $12.90 | $17.43 |
| Revenue Next Year | $5.15 | $13.22 |
| P/E Ratio | ★ $31.37 | $35.35 |
| Revenue Growth | 8.37 | ★ 14.21 |
| 52 Week Low | $30.18 | $54.11 |
| 52 Week High | $70.45 | $93.25 |
Technical Indicators
Market Signals| Indicator | LVS | DXCM |
|---|---|---|
| Relative Strength Index (RSI) | 76.06 | 54.34 |
| Support Level | $63.21 | $61.08 |
| Resistance Level | $65.92 | $64.00 |
| Average True Range (ATR) | 1.69 | 2.12 |
| MACD | 0.07 | 0.89 |
| Stochastic Oscillator | 90.21 | 94.49 |
Price Performance
Historical ComparisonAbout LVS Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner Macao, Four Seasons Hotel Macao, and Parisian Macao, as well as the Marina Bay Sands resort in Singapore. We expect Sands to open a fourth tower in Singapore in 2031. Its Venetian and Palazzo Las Vegas assets in the US were sold to Apollo and Vici in 2022. After the sale of its Vegas assets, the company generates all its EBITDA from Asia, with its casino operations generating the majority of sales.
About DXCM DexCom Inc.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.